1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. South and Central America Metastatic Cancer Drugs Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. South and Central America Metastatic Cancer Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. South and Central America Metastatic Cancer Drugs Market Regional Analysis
6.2 South and Central America Metastatic Cancer Drugs Market Revenue 2019-2028 (US$ Million)
6.3 South and Central America Metastatic Cancer Drugs Market Forecast Analysis
7. South and Central America Metastatic Cancer Drugs Market Analysis – by Cancer Type
7.1 Breast Cancer
- 7.1.1 Overview
- 7.1.2 Breast Cancer: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.2 Lung Cancer
- 7.2.1 Overview
- 7.2.2 Lung Cancer: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.3 Liver Cancer
- 7.3.1 Overview
- 7.3.2 Liver Cancer: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.4 Hematological Cancer
- 7.4.1 Overview
- 7.4.2 Hematological Cancer: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.5 Brain Cancer
- 7.5.1 Overview
- 7.5.2 Brain Cancer: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.6 Prostate Cancer
- 7.6.1 Overview
- 7.6.2 Prostate Cancer: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.7 Pancreatic Cancer
- 7.7.1 Overview
- 7.7.2 Pancreatic Cancer: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
8. South and Central America Metastatic Cancer Drugs Market Analysis – by Route of Administration
8.1 Intravenous and Intramuscular
- 8.1.1 Overview
- 8.1.2 Intravenous and Intramuscular: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9. South and Central America Metastatic Cancer Drugs Market Analysis – by Drug Class
9.1 HER2 Inhibitors
- 9.1.1 Overview
- 9.1.2 HER2 Inhibitors: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.2 Immune Checkpoint Inhibitors
- 9.2.1 Overview
- 9.2.2 Immune Checkpoint Inhibitors: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.3 PARP Inhibitors
- 9.3.1 Overview
- 9.3.2 PARP Inhibitors: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.4 Kinase Inhibitors
- 9.4.1 Overview
- 9.4.2 Kinase Inhibitors: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
10. South and Central America Metastatic Cancer Drugs Market Analysis – by Product
10.1 Branded
- 10.1.1 Overview
- 10.1.2 Branded: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
10.2 Generics
- 10.2.1 Overview
- 10.2.2 Generics: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
10.3 Biosimilars
- 10.3.1 Overview
- 10.3.2 Biosimilars: South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
11. South and Central America Metastatic Cancer Drugs Market – South and Central America Analysis
11.1 Overview
11.2 South and Central America
- 11.2.1 South and Central America Metastatic Cancer Drugs Market Breakdown, by Key
Country, 2022 and 2028 (%)
- 11.2.1.1 South and Central America Metastatic Cancer Drugs Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 Brazil:
South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.1.1 Brazil: South and Central America Metastatic Cancer Drugs Market Breakdown, by Cancer Type
- 11.2.1.1.2 Brazil: South and Central America Metastatic Cancer Drugs Market Breakdown, by Route of Administration
- 11.2.1.1.3 Brazil: South and Central America Metastatic Cancer Drugs Market Breakdown, by Drug Class
- 11.2.1.1.4 Brazil: South and Central America Metastatic Cancer Drugs Market Breakdown, by Product
- 11.2.1.2 Argentina:
South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.2.1 Argentina: South and Central America Metastatic Cancer Drugs Market Breakdown, by Cancer Type
- 11.2.1.2.2 Argentina: South and Central America Metastatic Cancer Drugs Market Breakdown, by Route of Administration
- 11.2.1.2.3 Argentina: South and Central America Metastatic Cancer Drugs Market Breakdown, by Drug Class
- 11.2.1.2.4 Argentina: South and Central America Metastatic Cancer Drugs Market Breakdown, by Product
- 11.2.1.3 Rest of South and Central America :
South and Central America Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.3.1 Rest of South and Central America : South and Central America Metastatic Cancer Drugs Market Breakdown, by Cancer Type
- 11.2.1.3.2 Rest of South and Central America : South and Central America Metastatic Cancer Drugs Market Breakdown, by Route of Administration
- 11.2.1.3.3 Rest of South and Central America : South and Central America Metastatic Cancer Drugs Market Breakdown, by Drug Class
- 11.2.1.3.4 Rest of South and Central America : South and Central America Metastatic Cancer Drugs Market Breakdown, by Product
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 AbbVie Inc.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Amgen Inc.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Bristol-Myers Squibb Company
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 F. HOFFMANN-LA ROCHE LTD.
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Novartis AG
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Astrazeneca
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 MERCK KGaA
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Pfizer Inc. (Arena Pharmaceutical GmbH)
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Johnson and Johnson Services, Inc.
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations